 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that...

ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy  (Epinephrine Nasal Spray)

Over the last three days, A.I.dvisor has detected that SPRY's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

ARS Pharmaceuticals (SPRY, $9.47) Aroon Indicator entered an Uptrend on April 01, 2024.

Yet again, the Oracle of Omaha has bolstered his stake in a media giant's tracking stocks. However, Warren Buffett was not the only one making notable insider purchases in the past week or so. An NFL...

Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO

Denali Advisors LLC bought a new stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the...

Denali Advisors LLC Makes New Investment in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) Director Ra Capital Management, L.P. purchased 505,954 shares of the stock in a transaction dated Wednesday, March 27th. The shares were...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Buys $4,953,289.66 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY  Get Free Report) insider Sarina Tanimoto sold 2,343 shares of the stock in a transaction on Friday, March 22nd. The shares were sold at an average price...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $21,133.86 in Stock

This is a signal that SPRY's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

ARS Pharmaceuticals (SPRY, $10.21) RSI Indicator left the overbought zone on March 28, 2024

ARS Pharmaceuticals (SPRY, $10.21) Aroon Indicator entered an Uptrend on March 28, 2024.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY  Get Free Report) Director Ra Capital Management, L.P. acquired 505,954 shares of the businesss stock in a transaction that occurred on Wednesday...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Ra Capital Management, L.P. Buys 505,954 Shares of Stock

ARS Pharmaceuticals (SPRY, $9.95) Aroon Indicator entered an Uptrend on March 27, 2024.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

Volume (M)	259,228.00
52-Wk High	$11.27
52-Wk Low	$2.55

SPRY ARS Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals